Frontiers in immunosuppression

Transplantation Proceedings

Volumn 43, Issue 3, 2011, Pages 822-825

  Kahan, B D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; A 770041; B7 ANTIGEN; BASILIXIMAB; BELATACEPT; CALCINEURIN; CD86 ANTIGEN; CYCLOSPORIN; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; EMODIN; EVEROLIMUS; I KAPPA B KINASE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; JANUS KINASE 2 INHIBITOR; JANUS KINASE 3; JANUS KINASE 3 INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN KINASE C; PROTEIN KINASE LCK; PROTEIN KINASE ZAP 70; RAPAMYCIN; SOTRASTAURIN; STEROID; STEROID RECEPTOR; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; LYMPHOPROLIFERATIVE DISEASE; NEPHROTOXICITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TACHYCARDIA;

GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION;

EID: 79954495419     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.02.001     Document Type: Conference Paper

References (15)

1. W. Waegell, M. Babineau, and M. Hart A420983, a novel, small molecule inhibitor of Lck prevents allograft rejection Transplant Proc 34 2002 1411
2. Y.X. Liu, N.Y. Shen, and C. Liu Immunosuppressive effects of emodin: an in vivo and in vitro study Transplant Proc 41 2009 1837
3. F. Vincenti, C. Larsen, and A. Durrbach Costimulation blockade with belatacept in renal transplantation N Engl J Med 353 2005 770
4. F. Vincenti, C. Larsen, and A. Durrbach Five year safety and efficacy of belatacept in renal transplantation J Am Soc Nephrol 21 2010 1587
5. F. Vincenti, B. Charpentier, and Y. Vanrenterghem A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study) Am J Transplant 10 2010 535
6. A. Durrbach, J.M. Pestana, and T. Pearson A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study) Am J Transplant 10 2010 547
7. K. Budde, C. Sommerer, and T. Becker Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients Am J Transplant 10 2010 571
8. E. Kudlacz, B. Perry, and P. Sawyer The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models Am J Transplant 4 2004 51
9. D.C. Borie, M.J. Larson, and M.G. Flores Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates Transplantation 80 2005 1756
10. S. Busque, J. Leventhal, and D.C. Brennan Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients Am J Transplant 9 2009 1936
11. F. Vincenti, H. Tedesco-Silva, and S. Busqlue Phase 2B study of CNI-free immunosuppression with the Jak 3 inhibitor CP-690, 550 in de novo kidney transplant patients Am J Transplant 10 suppl 4 2010 211
12. M.W. Karaman, S. Herrgard, and D.K. Treiber A quantitative analysis of kinase inhibitor selectivity Nat Biotechnol 26 2008 127
13. D.M. Meyer, M.I. Jesson, and X. Li Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis J Inflamm (Lond) 7 2010 41
14. P. Gupta, L.E. Friberg, and M.O. Karlsson A semi-mechanistic model of CP-690,550-induced reduction in neutrophil counts in patients with rheumatoid arthritis J Clin Pharmacol 50 2010 679
15. J.M. Kremer, B.J. Bloom, and F.C. Breedveld The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo Arthritis Rheum 60 2009 1895